Immatics (IMTX)

• Market cap: $1.32B
• 1 day: 6.17%
• 5 days: 2.94%
• 1 month: -1.21%
• 3 months: -2.78%
• 6 months: 63.5%
• Year to date: -6.12%
• 1 year: 96.99%
• 5 years: -15.65%
• 10 years: 2.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Employees: 423